Literature DB >> 7862918

Transdermal nicotine: reduction of smoking with minimal abuse liability.

W B Pickworth1, E B Bunker, J E Henningfield.   

Abstract

Cigarette consumption as well as the physiologic, performance and subjective effects of the nicotine patch were evaluated in ten subjects who smoked ad libitum while residing on a residential research ward for 30 days. Nicotine transdermal systems ("patches") delivering a total of 0, 22 or 44 mg per 24 h were applied daily at a constant dose during each 7-day condition; the order of dosing conditions was varied according to a randomized, double-blind, crossover design. Nicotine patches significantly but modestly reduced spontaneous smoking and significantly increased venous plasma nicotine levels. Self ratings of patch liking, satisfaction with cigarettes and the ability to identify the patch condition did not change as a function of the nicotine dose, indicating minimal abuse liability. There were no consistent changes in the puffing pattern measures; however, in all patch conditions, subjects with extensive histories of illicit drug use smoked cigarettes faster than subjects with histories of occasional drug use. Small changes in resting heart rate, pulse and blood pressure occurred when the nicotine patch was worn. Thus large changes in venous plasma nicotine levels engender only modest changes in ad libitum cigarette consumption, measures of abuse liability and cardiovascular effects. These findings are consistent with the notion that the addictive and toxic effects of nicotine are partially determined by the rate of drug administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862918     DOI: 10.1007/bf02244745

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test.

Authors:  H F FRASER; G D VAN HORN; W R MARTIN; A B WOLBACH; H ISBELL
Journal:  J Pharmacol Exp Ther       Date:  1961-09       Impact factor: 4.030

2.  The relationship between chronic ethanol exposure and cigarette smoking in the laboratory and the natural environment.

Authors:  R M Keenan; D K Hatsukami; R W Pickens; S W Gust; L J Strelow
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Effect of nicotine chewing gum on smoking behaviour and as an aid to cigarette withdrawal.

Authors:  M A Russell; C Wilson; C Feyerabend; P V Cole
Journal:  Br Med J       Date:  1976-08-14

4.  Clinical and pharmacokinetic properties of a transdermal nicotine patch.

Authors:  S C Mulligan; J G Masterson; J G Devane; J G Kelly
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

5.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment.

Authors:  K O Fagerström
Journal:  Addict Behav       Date:  1978       Impact factor: 3.913

6.  The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid.

Authors:  B R Lucchesi; C R Schuster; G S Emley
Journal:  Clin Pharmacol Ther       Date:  1967 Nov-Dec       Impact factor: 6.875

7.  Nicotine regulation and cigarette smoking.

Authors:  L T Kozlowski; M E Jarvik; E R Gritz
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

8.  Effect of nicotine chewing gum on plasma nicotine levels of cigarette smokers.

Authors:  R V Ebert; M E McNabb; S L Snow
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

Review 9.  Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation.

Authors:  K J Palmer; M M Buckley; D Faulds
Journal:  Drugs       Date:  1992-09       Impact factor: 9.546

10.  Transdermal nicotine and smoking behavior in psychiatric patients.

Authors:  N Hartman; G B Leong; S M Glynn; J N Wilkins; M E Jarvik
Journal:  Am J Psychiatry       Date:  1991-03       Impact factor: 18.112

View more
  18 in total

1.  Anti-Smoking therapies: is harm reduction a viable alternative to smoking cessation?

Authors:  J P Zellweger
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects.

Authors:  Caroline O Cobb; Alan Shihadeh; Michael F Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2010-12-02       Impact factor: 4.244

Review 3.  Medication screening for smoking cessation: a proposal for new methodologies.

Authors:  Kenneth A Perkins; Maxine Stitzer; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

Review 4.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

5.  Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies.

Authors:  J P Shaw; D G Ferry; D Pethica; D Brenner; I G Tucker
Journal:  Tob Control       Date:  1998       Impact factor: 7.552

6.  Electronic cigarette user plasma nicotine concentration, puff topography, heart rate, and subjective effects: Influence of liquid nicotine concentration and user experience.

Authors:  Marzena Hiler; Alison Breland; Tory Spindle; Sarah Maloney; Thokozeni Lipato; Nareg Karaoghlanian; Alan Shihadeh; Alexa Lopez; Carolina Ramôa; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.157

7.  Abuse liability assessment of an electronic cigarette in combustible cigarette smokers.

Authors:  Sarah F Maloney; Alison Breland; Eric K Soule; Marzena Hiler; Carolina Ramôa; Thokozeni Lipato; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2019-02-18       Impact factor: 3.157

8.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

9.  Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects.

Authors:  Tory R Spindle; Alison B Breland; Nareg V Karaoghlanian; Alan L Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2014-09-19       Impact factor: 4.244

10.  Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.

Authors:  C O Cobb; M F Weaver; T Eissenberg
Journal:  Tob Control       Date:  2009-04-02       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.